CN1186027C - Cancer-treating Chinese medicine and its prepn - Google Patents
Cancer-treating Chinese medicine and its prepn Download PDFInfo
- Publication number
- CN1186027C CN1186027C CNB011202351A CN01120235A CN1186027C CN 1186027 C CN1186027 C CN 1186027C CN B011202351 A CNB011202351 A CN B011202351A CN 01120235 A CN01120235 A CN 01120235A CN 1186027 C CN1186027 C CN 1186027C
- Authority
- CN
- China
- Prior art keywords
- solution
- grams
- chinese patent
- cancer
- patent medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 19
- 201000011510 cancer Diseases 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000008014 freezing Effects 0.000 claims abstract description 10
- 238000007710 freezing Methods 0.000 claims abstract description 10
- 241000271039 Agkistrodon Species 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 210000001835 viscera Anatomy 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 12
- 241001312741 Gekko swinhonis Species 0.000 claims description 10
- 241000272074 Bungarus Species 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 4
- 241001597062 Channa argus Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002002 slurry Substances 0.000 abstract 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 2
- 241000271897 Viperidae Species 0.000 abstract 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052737 gold Inorganic materials 0.000 abstract 2
- 239000010931 gold Substances 0.000 abstract 2
- 229910052709 silver Inorganic materials 0.000 abstract 2
- 239000004332 silver Substances 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 239000010419 fine particle Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000005619 esophageal carcinoma Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000007163 Livistona chinensis Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000008922 delisheng Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000008602 kang-lai-te Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000009333 tian-xian Substances 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to Chinese patent medicine for treating cancer, which is composed of alive medicinal animals. The present invention has the components of the following proportion 50% or 1500 grams of gecko, 25% or 750 grams of gold and silver long-noded pit viper and 25% or 750 grams of agkistrodon. The viscera of the gecko is removed, the snake head and the viscus are removed; after washed, the gecko, the gold and silver long-noded pit viper and the agkistrodon are cut into brawn; under the low temperature of-30 DEG C to 196 DEG C, the brawn is minced, equiponderant water is added in the brawn, and the mixture is uniformly prepared into slurry. After the slurry is frozen for 24 hours under the temperature of-20 DEG C to 50 DEG C, the slurry is taken out and is put in water of 37 DEG C to melt; the solution is repeatedly filtered for three to five times, the solution is centrifugally extracted; ultrafiltration is carried out to the filtered solution, and the solution is put in vacuum to be frozen; after the solution is dried, the solution is made into fine particles which are filled in capsules; besides, the solution can be made into a mixture by drying. The medicine has the advantage of high capability of resisting cancer; besides, animals are used as raw materials; the adoption of a freezing preparation process belongs to a pioneer.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine for the treatment of cancer and preparation method thereof, it can make capsule or mixture, belongs to technical field of Chinese medicine.
Background technology
Cancer is the disease of serious harm people's life, annual number of the infected up to 2,000,000 people about, also be to leap to the die first place of reason of disease, the control of cancer and research are just becoming the problem that whole world medical science is concerned about day by day.Its popularity and research have tentatively been grasped to the cause of disease in recent years rapidly, to the study on prevention of cancer progress.
Existing cancer Chinese medicine, for example FUFANG TIANXIAN JIAONANG has certain inhibitory action to treatment esophageal carcinoma, gastric cancer, can significantly suppress ehrlich ascites carcinoma, colorectal cancer, remission rate 1.2%, coefficient of stabilization is 77%; And for example capsule with pseudo-ginseng and Chinese fanpalm seed is used for the treatment of late gastric cancer, esophageal carcinoma, GANFULE PIAN cures mainly primary hepatocarcinoma, upper limb lump, DELISHENG ZHUSHEYE is used for mid and late liver cancer, the An Tike capsule cures mainly esophageal carcinoma silt toxication, total remission rate is 7.86%, share with chemotherapy and can improve 37.62%, KANGLAITE ZHUSHEYE all has the obvious suppression effect to multiple transplanted tumor, human hepatocellular, and living lotus capsule mainly curing cancer of lung, gastric cancer and coefficient of stabilization reach 82%.In sum, as seen these control the cancer medicine all certain curative effect, and these medicines all are to make with medicinal plant, but effect is also unsatisfactory.
Summary of the invention
The present invention is a kind of Chinese patent medicine for the treatment of cancer and preparation method thereof.This medicine is made raw material by three kinds of fresh and alive animals, and is made by certain proportioning; It can capture cancerous cell again can reinforcing body resistance, and does not also damage body, and confirming from pharmacological tests can enhancing body's immunological function, can suppress the growth of tumor body again, prevention of postoperative cancerous cell recurrence or shift, and it has reached the level of molecular cell research.Its manufacture method adopts freezing modern biochemical technology to extract its effective ingredient, has preserved the molecule ecological balance of natural drug.
The explanation of summary of the invention
A kind of Chinese patent medicine for the treatment of cancer, it is to be made by the medicinal animal of following weight proportioning:
Bright Gekko Swinhonis 1500 grams or 50%, bright Bungarus Parvus 750 grams or 25% and bright Agkistrodon 750 grams or 25%.
The method for making of the Chinese patent medicine of treatment cancer is as follows:
Bright Agkistrodon 750 grams of bright Bungarus Parvus 750 grams of bright Gekko Swinhonis 1500 grams
Get fresh and alive Gekko Swinhonis and take out its internal organs by said ratio, Bungarus Parvus and Agkistrodon are all removed its head and internal organs are cleaned, then with 70～75% alcohol disinfecting and cut the generate meat paste, in low temperature-30～196 ℃ rubbing down, the water that adds equivalent mix well pulping and be placed on-20～-50 ℃ freezing 24 hours, take out in the water that is placed on 37 ℃ again and melt, filter (filtration of detailed catalogue 60-200 order) repeatedly the speed centrifugalize of filtrate through 3-5 time with 8000 rev/mins, draw its supernatant and carry out the ultrafiltration of (5000-10000), in filtrate, add B one cyclodextrin 150-180 gram inclusion, in vacuum pump, carry out freezing, dry and be ground into fine grained after incapsulate, carry out packing then and be packaged into finished product.Also can after 8000 rev/mins speed centrifugalize, carry out vacuum freezing, carry out making the mixture finished product for the treatment of the cancer Chinese patent medicine after the packing sterilization.
The discriminating of bright Gekko Swinhonis, Agkistrodon and contrast medicine shows identical fluorescent speckle on the corresponding position of chromatograph.The content of this product polypeptide represents that with protein the qualification degree is every and is no less than 7.0mg.
Aspect toxicologic study, carried out acute toxicity test, proportionately 926 of people's consumption times once oral to mice, it is all normal to observe after seven days mice, no acute toxic reaction; Long term toxicity test has also been confirmed hepatic and renal function and vitals are not all represented toxic reaction.Gekko Swinhonis in the prescription is real to be no web Gekko Swinhonis, goes into the saturating muscle of blood system and reaches network, can the removing blood stasis powder detoxifcation can lead to again that muscle reaches network and pain relieving is applicable to constitutional hepatitis, blood stasis pent-up disease.
This medicine is not a single component, and it has the characteristics of many compositions, micromolecule, high-load, high activity and reasonable mixture ratio.Each composition is brought into play synergism between mutually, and collection nutrition, metabolism, immunity and tumor necrosis factor etc. act on one, and the regulative mechanism balance can be considered the cancer therapy drug of " biological response modifier " class.
The advantage of this treatment cancer Chinese patent medicine is:
1. the fresh and alive medicinal animal of this medicine (comprising capsule or mixture) employing is a raw material, and this is discovery of original creation.
2. adopting freezing and modern biochemical separation and extraction technology also is domestic initiation.
3. flavour of a drug are fewer but better, reasonable mixture ratio, and synergy is good, can attack cancerous cell and can set upright gas again and not damage body.
4. the immunologic function of energy active cell improves NK (killer cell) activity.
The specific embodiment
Get bright Gekko Swinhonis 1500 grams, bright Bungarus Parvus 750 grams, bright Agkistrodon 750 grams are raw material, remove the internal organs of Gekko Swinhonis, snakehead and internal organs also clean up, cut into meat paste after disinfecting in alcohol and under-30～-196 ℃ low temperature, rub, the water that adds equivalent mix well pulping and be placed on-20～-50 ℃ freezing 24 hours, take out in the water that is placed on 37 ℃ again and melt, filter (detailed catalogue 60-200 order) repeatedly through 3-5 time, the speed centrifugalize of filtrate with 8000 rev/mins, draw the ultrafiltration that its supernatant carries out (5000-10000), in filtrate, add B one cyclodextrin 150-180 gram, through inclusion, freezing, crushed after being dried becomes to incapsulate behind the fine grained or the ultrafiltration final vacuum is frozen into the mixture finished product.
Claims (3)
1. a Chinese patent medicine for the treatment of cancer is characterized in that it is to be made by the medicinal animal of following weight proportioning: bright Gekko Swinhonis 1500 grams, bright Bungarus Parvus 750 grams, bright Agkistrodon 750 grams.
2. the Chinese patent medicine of treatment cancer according to claim 1, the dosage form that it is characterized in that described Chinese patent medicine is capsule or mixture.
3. the preparation method of the Chinese patent medicine of treatment cancer according to claim 1, it is characterized in that: the internal organs of removing Gekko Swinhonis, head of Bungarus Parvus and Agkistrodon and internal organs also clean up, cut into meat paste with cutting behind 70～75% the alcohol disinfecting, after the water of low temperature-30～-196 ℃ following rubbing and interpolation equivalent is mixed well pulping, place-20～-50 ℃ freezing 24 hours, take out in the water that is placed on 37 ℃ again and melt, filter repeatedly through 3-5 time, the speed centrifugalize of filtrate with 8000 rev/mins, draw its supernatant and carry out ultrafiltration, in filtrate, add β one cyclodextrin 150-180 gram inclusion, in vacuum pump, carry out freezing, dry, and incapsulate after being ground into fine grained, carry out packing then, packing is made finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011202351A CN1186027C (en) | 2001-07-11 | 2001-07-11 | Cancer-treating Chinese medicine and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011202351A CN1186027C (en) | 2001-07-11 | 2001-07-11 | Cancer-treating Chinese medicine and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1337254A CN1337254A (en) | 2002-02-27 |
| CN1186027C true CN1186027C (en) | 2005-01-26 |
Family
ID=4664001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011202351A Expired - Lifetime CN1186027C (en) | 2001-07-11 | 2001-07-11 | Cancer-treating Chinese medicine and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1186027C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1322014C (en) * | 2004-06-17 | 2007-06-20 | 吴雄志 | Gecko polysaccharide, and its preparing method and pharmaceutical use |
| CN102228478B (en) * | 2011-06-17 | 2012-11-14 | 北京建生药业有限公司 | Medicinal composition for treating blood stasis and qi stagnation syndrome of primary liver cancer and preparation method thereof |
| CN102331460B (en) * | 2011-06-17 | 2013-07-17 | 北京建生药业有限公司 | Fresh animal pharmaceutical composition and fingerprint detecting method for fresh gecko powder |
| CN102338782B (en) * | 2011-06-17 | 2013-02-06 | 北京建生药业有限公司 | Fresh animal medicinal composition and method for measuring content of Chinese medicines of fresh animal medicinal composition |
| CN109758480B (en) * | 2019-03-27 | 2021-01-12 | 景德镇陈锋特种野生动物科技开发有限公司 | Preparation method of Agkistrodon acutus lyophilized powder for rheumatoid arthritis |
| CN115444866A (en) * | 2022-08-23 | 2022-12-09 | 广西金圣堂生物医药科技有限公司 | Application of cobra powder or water extract thereof in preparation of anti-liver cancer drugs |
-
2001
- 2001-07-11 CN CNB011202351A patent/CN1186027C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1337254A (en) | 2002-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101559084B (en) | Anti-tumor pharmaceutical composition and preparation method thereof | |
| CN101961371B (en) | Method for extracting and separating ginsenoside, flavone and polysaccharide from sweet gynostemma pentaphylla | |
| CN101485789A (en) | Camellia chrysantha polysaccharide lozenge and method for producing the same | |
| JPH11199497A (en) | Stimulant to organism | |
| CN110772630A (en) | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| WO2021078288A1 (en) | Activated insulin, compound momordica charantia peptide oral medicine for treatment of diabetes, and preparation method | |
| CN1186027C (en) | Cancer-treating Chinese medicine and its prepn | |
| CN108383224A (en) | A kind of flocculant of environmentally protective degerming | |
| CN112741851A (en) | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules | |
| CN105030812A (en) | Compound fungal polysaccharide capsule | |
| KR100227609B1 (en) | Preparation of health food made of houttuynia cordata and seaweed | |
| CN112656937B (en) | Bovine bone collagen peptide composition and preparation method and application thereof | |
| CN101972284B (en) | Preparation method of pine needle fat soluble extract and application thereof in preparing drug for treating gastric ulcer | |
| CN111419999B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| KR20050101143A (en) | Methods and composition for the prevention and improvement of degenerative arthritis including glucosamin | |
| CN113729153A (en) | Formula and preparation method of plant selenium earthworm and tempeh tablet | |
| JPH0245501A (en) | Chikusetsu ginseng polysaccharide and use thereof | |
| CN115671219B (en) | Traditional Chinese medicine composition for treating gout and preparation method and application thereof | |
| CN112516174B (en) | A product containing internal organs of sea intestine and its preparation method | |
| CN1586500A (en) | Disodium cantharidinate injection for treating tumor and its preparing method | |
| KR20130012417A (en) | Composition for immune boosting having radioprotective effect comprising fucoidane from ecklonia cava extracts | |
| Khalaf et al. | Evaluation of the Anti-inflammatory and Anti-oxidant Activity of Crab Components and Crab Shell in Experimental Rats in Comparison with Dexamethasone and Diclofenac Sodium | |
| CN113181173B (en) | Medicinal composition and application thereof in preparing products for preventing and/or treating liver cancer | |
| KR100740716B1 (en) | Composition comprising the extract of Buckwheat for prevention and control of thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Jiansheng Document name: Notice of first review |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090109 Address after: No. 8, Yong Sheng street, Miyun Industrial Development Zone, Beijing Patentee after: Beijing Jiansheng Pharmaceutical Co.,Ltd. Address before: 36, Fuxing Road, Fuxing Road, Beijing, Haidian District, A2-210 Patentee before: Li Jiansheng |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING JIANSHENG PHARMACY CO., LTD. Free format text: FORMER OWNER: LI JIANSHENG Effective date: 20090109 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050126 |
|
| CX01 | Expiry of patent term |